This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk-stratified protocol in young adults (18-30 years) with classical Hodgkin Lymphoma. The primary end-point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5-19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) rate. Twelve months disease-free survival (DFS) was 91%. We demonstrate that a risk-stratified paediatric combined modality treatment approach can be delivered to young adults without significant irreversible neuropathy.

中文翻译：

---

用改良的小儿霍奇金淋巴瘤治疗方案治疗18-30岁的年轻人中的经典霍奇金淋巴瘤。多中心II期临床试验（CRUK / 08/012）的结果。

这项II期临床试验旨在确定改良的儿科风险分层方案在经典霍奇金淋巴瘤（18-30岁）的年轻成年人中的安全性和有效性。主要终点是神经毒性率。3级神经毒性的发生率为11％（CI为80％，5-19％）；不能排除超过15％的真实神经病变率。神经病和相关的生活质量下降在很大程度上是可逆的。总体缓解率为100％，完全缓解（CR）率为40％。十二个月的无病生存期（DFS）为91％。我们证明，可以将风险分层的儿科联合治疗方法交付给没有明显不可逆神经病的年轻人。